Key Insights

Highlights

Treatment Research

5 treatments under study, led by Hop Bundle

Research Leaders

20 sponsors active, led by The Second Affiliated Hospital of Jiaxing University

Related Conditions

Often studied with 15 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 4 (1)

Trial Status

Recruiting4

Clinical Trials (4)

Showing 4 of 4 trials
NCT07875582Recruiting

Diagnostic Utility of Protein Biomarkers in Pancreatic Ductal Adenocarcinoma

NCT07262957Phase 4Recruiting

Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)

NCT07117045Recruiting

Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer

NCT06638866Recruiting

AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort

Showing all 4 trials

Research Network

Common Treatments

  • Hop Bundle1
  • Pancreatic Precursor Lesions1
  • Bloodbased Protein Biomarker Assessment1
  • Diagnostic Evaluation For Positive Ai Findings1
  • Pdac1

Active Sponsors

  • The Second Affiliated Hospital of Jiaxing University2
  • Changhai Hospital2
  • University Hospital, Antwerp1
  • Clinical Cancer Hospital, Kyiv1
  • Institutul Clinic Fundeni1

Top Investigators

Related Conditions

  • Intraductal Papillary Mucinous Neoplasm3
  • Pancreatic Cancer3
  • Pdac Pancreatic Ductal Adenocarcinoma2
  • Pancreatic Ductal Adenocarcinoma1
  • Ipmn Pancreatic1

Activity Timeline